NCT05507242RecruitingPhase 2
Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of Tezepelumab
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Feb 2026
Brief summary (registry, in English)
To evaluate the effect of tezepelumab on eosinophilic bronchial mucosal tissue inflammation.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 25 Apr 2024
- Start date
- 9 May 2024
- Lead sponsor
- Region Hovedstaden
- Diseases
- COPD
- NCT number
- NCT05507242
- EU CT number
- 2024-511730-12-00
- EudraCT number
- 2022-000179-38
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exacerbation requiring oral corticosteroids or antibiotics (any dose for more than 3 days) 4 weeks prior to Visit 1 or during the run-in period
- Any use of home oxygen therapy
- Lung volume reduction surgery for COPD
Who the study is looking for
- Subjects with COPD on LABA+LAMA±ICS with ≥ 1 exacerbation the past 12 months
- Postbronchodilator FEV1 ≥ 30% predicted (and ≥ 1.0L) and < 80% predicted
- Age 40 years or older
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Respiratory Research unit, Bispebjerg Hospital Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.